Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Revenue projections:

Revenue projections for ASTRAZEN
Revenue projections for ASTRAZEN



Financial Ratios:

currentRatio 1.90900
forwardPE 0.00000
debtToEquity 4.63800
earningsGrowth 0.47600
revenueGrowth 0.25400
grossMargins 0.43890
operatingMargins 0.14294
trailingEps 46.68000
forwardEps 0.00000

ASTRAZEN's current ratio of 1.909 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. ASTRAZEN's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
ASTRAZEN's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with ASTRAZEN expected to increase its market presence and profitability.